Literature DB >> 8751000

[Idiopathic juxtafoveolar telangiectasis. Long-term follow-up of visual acuity].

A Kiraly1, J E Nasemann.   

Abstract

The beneficial effect of laser therapy on idiopathic juxtafoveolar telangiectasis is questionable. We therefore studied retrospectively the spontaneous course of the disease and tried to show a correlation between the initial angiographic findings and visual outcome. In addition, the results after laser therapy were compared with untreated patients. Thirteen patients (24 eyes) with idiopathic juxtafoveolar telangiectasis diagnosed by fluorescein angiography were reexamined after a mean time interval of 38 months. Argon laser coagulation had been performed in 6 patients. The initial extension of fluorescein leakage was divided angiographically into three different stages. The existence of secondary macular changes and peripheral involvement was noted. The mean visual acuity decreased from 0.71 to 0.62 over the follow-up period. No correlation could be found between the final visual outcome and initial extension of telangiectasis or existence of secondary changes. After laser coagulation the patients did not show a better visual outcome. Due to the relatively benign spontaneous course of idiopathic juxtafoveolar telangiectasis laser coagulation cannot be recommended in general. Only in exceptional cases (e.g., development of subretinal neovascularization) can laser coagulation be of benefit.

Entities:  

Mesh:

Year:  1995        PMID: 8751000

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  2 in total

Review 1.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

2.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.